The Latest Breaking News on Pharma

Investors who bought stocks during the COVID-19 market crash in 2020 have generally experienced some big gains in the past two years. But there is no question some big-name stocks performed better than others since the pandemic bottom.

The U.S. Food and Drug Administration (FDA) has approved Bluebird bio’s (NASDAQ:BLUE) lead asset ZYNTEGLO (betibeglogene autotemcel) to treat the underlying genetic cause of beta‑thalassemia in adult and pediatric patients who require regular red blood cell (RBC) transfusions. Bluebird shares traded in a range of $6.13 to $8.18 on a day…

The legislation has been a year in the making, with tense negotiations leading to a narrower spending package that focuses on climate investments and health care costs.

A new FDA rule allows adults with perceived mild to moderate hearing loss to buy hearing aids over the counter. Efforts to make them more affordable and accessible have been in the works for years.

Substantial investments in R&D, an aging population, and growing demand for advanced drugs to treat chronic diseases should drive the pharmaceutical industry’s growth. Therefore, investing in fundamentally strong and dividend-paying pharma stocks Johnson & Johnson (JNJ) and Bristol-Myers Squibb (BMY) could help dodge the current market volatility and generate substantial…

A suspicious dump of Shkreli's newly created crypto token may have been the result of malware disguised as porn.

JCVI says mRNA vaccines such as the Pfizer and Moderna jabs are the most effective for UK booster programme

The biotech industry is expected to see solid growth in the long term due to rising healthcare spending, breakthrough developments, and an aging population. Given the industry’s solid growth prospects and non-cyclical nature, it could be wise to invest in fundamentally strong biotech stocks Gilead Sciences (GILD), Biogen (BIIB), Jazz…

Vertex Pharmaceuticals (VRTX) is a high-quality biotech stock that is quite cheap with impressive growth prospects. Read on to find out why it’s our growth stock of the week….